What is the appropriate treatment for sinus aspergillosis?

Treatment of Sinus Aspergillosis

The treatment of sinus aspergillosis depends critically on the clinical form: allergic rhinosinusitis requires polypectomy and sinus washout with intranasal corticosteroids, while invasive forms demand surgical debridement combined with systemic antifungal therapy (voriconazole as first-line), and non-invasive aspergilloma (fungal ball) is managed with surgical resection alone without antifungals 1.

Treatment Algorithm by Clinical Form

1. Allergic Aspergillus Rhinosinusitis (Non-Invasive)

• Primary treatment: Polypectomy and sinus washout with intranasal corticosteroids 1
• Antifungal therapy: Reserved only for refractory or relapsing cases 1
• If systemic therapy needed: Itraconazole is preferred, with voriconazole (200 mg PO every 12 hours) or posaconazole as alternatives 1
• Corticosteroids remain the cornerstone for exacerbations, with itraconazole providing corticosteroid-sparing effects 1

2. Aspergilloma (Fungal Ball/Saprophytic Form)

• Primary treatment: Surgical resection alone 1
• No antifungal therapy typically needed - the role of medical therapy is uncertain as penetration into preexisting cavities is minimal for amphotericin B 1
• Surgery remains the treatment of choice for mycetoma of the paranasal sinuses 2
• Recent evidence confirms complete surgical removal via endoscopic approaches (such as bone lid technique) achieves excellent outcomes without antifungals 3

3. Invasive Aspergillus Sinusitis

This is the most critical form requiring aggressive combined therapy:

Surgical Management (Essential First Step)

• Surgery is mandatory for localized invasive disease that is easily accessible to debridement 1
• Endoscopic sinus surgery with complete removal of fungal burden whenever feasible 4, 5
• Combined transcranial and endonasal approaches may be necessary for orbitocranial extension 4
• Critical pitfall: Delay in surgical intervention increases mortality, especially with vascular invasion risk 6, 4

Antifungal Therapy (Combined with Surgery)

First-line systemic therapy:

• Voriconazole (loading dose: 6 mg/kg IV every 12 hours for 1 day, then 4 mg/kg IV every 12 hours; oral: 200-300 mg every 12 hours) 1

Alternative therapies (in order of preference):

• Liposomal amphotericin B (3 mg/kg/day IV) 1
• Isavuconazole 1
• Other lipid formulations of amphotericin B 1

For chronic invasive forms in immunocompetent patients:

• Itraconazole alone may be curative 2
• Monitor liver function tests and drug interactions 2
• Imaging required to monitor resolution; remineralization occurs after approximately 6 months 2

For inoperable invasive disease:

• Combination therapy with micafungin plus high-dose itraconazole (400 mg daily oral solution) has shown success 6
• Voriconazole plus echinocandin combination may be considered in select documented cases 1

Duration of Treatment

• Minimum 6-12 weeks for invasive pulmonary aspergillosis, largely dependent on degree and duration of immunosuppression, site of disease, and evidence of improvement 1
• Chronic invasive forms may require 3-12 months 4

Adjunctive Measures

• Reduce or eliminate immunosuppressive agents when feasible 1
• Colony-stimulating factors may be considered in neutropenic patients 1
• Granulocyte transfusions for refractory cases in neutropenic patients with anticipated neutropenia >1 week 1

Key Clinical Distinctions

Immunocompetent vs Immunocompromised:

• Immunocompetent patients typically develop localized invasive infection or non-invasive forms 7
• Immunocompromised patients (diabetes, COVID-19, hematologic malignancy) are at high risk for extensive invasive disease with high mortality 8, 7

Critical Warning Signs Requiring Aggressive Intervention:

• Orbitocranial extension 4
• Visual symptoms (decreased acuity, diplopia) 8
• Vascular invasion risk 6, 4
• Subarachnoid hemorrhage 4

Common Pitfalls to Avoid

1. Do not use antifungals alone for invasive forms - surgery is essential 1
2. Do not routinely use antifungals for simple aspergilloma - surgical removal is sufficient 1, 3
3. Do not use echinocandins as primary monotherapy - they are not recommended as first-line 1
4. Do not delay treatment in invasive forms - high mortality risk with vascular invasion 6, 4
5. Monitor for recurrence: 25% may have sinonasal recurrence requiring repeat endonasal evacuation 4